HSR22-177: Real-World Utilization of Lenvatinib+Pembrolizumab Combination Therapy for the Treatment of Advanced Endometrial Cancer in the United States: ENdometrial cancer DOsing in the real-World (ENDOW) Study

Keiko Wada,Vimalanand Prabhu,Yi Wang,Jingchuan Zhang

Journal of the National Comprehensive Cancer Network（2022）

引用 0|浏览3

暂无评分

摘要

"HSR22-177: Real-World Utilization of Lenvatinib+Pembrolizumab Combination Therapy for the Treatment of Advanced Endometrial Cancer in the United States: ENdometrial cancer DOsing in the real-World (ENDOW) Study" published on 31 Mar 2022 by National Comprehensive Cancer Network.

查看译文

关键词

endometrial cancer dosing,advanced endometrial cancer,real-world,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要